Empowered Funds LLC Invests $13.91 Million in AnaptysBio, Inc. $ANAB

Empowered Funds LLC acquired a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 206,010 shares of the biotechnology company’s stock, valued at approximately $13,906,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. BlackRock Inc. purchased a new position in AnaptysBio in the second quarter valued at $124,473,000. Affinity Asset Advisors LLC boosted its stake in shares of AnaptysBio by 111.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock worth $52,132,000 after acquiring an additional 495,308 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of AnaptysBio during the 2nd quarter valued at about $28,202,000. JPMorgan Chase & Co. grew its position in shares of AnaptysBio by 1,631.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after acquiring an additional 233,325 shares during the period. Finally, Voloridge Investment Management LLC increased its stake in shares of AnaptysBio by 2,358.3% in the 4th quarter. Voloridge Investment Management LLC now owns 229,137 shares of the biotechnology company’s stock valued at $11,109,000 after purchasing an additional 219,816 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ANAB. UBS Group boosted their price objective on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. TD Cowen cut their price target on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday. Leerink Partners set a $90.00 price objective on shares of AnaptysBio in a research report on Friday, May 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $95.00 price objective on shares of AnaptysBio in a report on Monday, August 24th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $80.00.

AnaptysBio Stock Performance

ANAB stock opened at $56.28 on Friday. AnaptysBio, Inc. has a one year low of $11.40 and a one year high of $72.36. The firm has a market cap of $1.67 billion, a PE ratio of -52.11 and a beta of 0.72. The firm’s 50 day moving average price is $58.55 and its 200-day moving average price is $59.06.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.